Dr. Yair Lotan, UTSW, presented on BLC with Cysview for surveillance Dr. Yair Lotan M.D., Professor of Urology, UT Southwestern Medical Center and the lead author on a new Consensus paper for use of ...

Photocure ASA, the bladder cancer company, announces the start of its Cysview sales, marketing and distribution operations in the Canadian market. In August 2021 Photocure had reached an agreement ...

The FDA has approved Cysview (hexaminolevulinate HCl, from GE Healthcare), an optical imaging agent, for use in the cystoscopic detection of non-muscle-invasive papillary cancer of the bladder among ...

(RTTNews) - Photocure ASA (PHCUF.PK), a Norwegian specialty pharma company, said on Monday that it has started sales, marketing, and distribution operations of Cysview in Canada. Cysview is an optical ...

OSLO, Norway, Nov. 5, 2019 /PRNewswire/ -- Photocure ASA., (OSE: PHO), The United States Centers for Medicare and Medicaid Services (CMS) has released its Final Rule maintaining the reimbursement code ...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--The KARL STORZ Photodynamic Diagnosis (PDD) System - Blue Light Cystoscopy with Cysview (BLCC) is one of the medical innovations that was showcased in front of ...

Oslo, Norway, May 12th, 2017: Photocure ASA (Photocure, PHO:OSE), today announced that a Phase 3 trial investigating Blue Light Flexible Cystoscopy (BLFC(TM)) with Cysview®/Hexvix® in the surveillance ...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., announces the commercial launch of the PDD Blue Light Flexible Video Cystoscopy System for enhanced detection of non-muscle ...

FOX CHASE, Pa. -- Bladder cancer is one of the most common cancers - just behind melanoma. Yet, many people don't know much about it. Doctors are now using a diagnostic tool to better find and ...

OSLO, Norway, Feb. 19, 2025 /PRNewswire/ --Photocure ASA (OSE:PHO) today reported Hexvix ® /Cysview ® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK 114.2 million) and ...